Three‐year efficacy and safety of certolizumab pegol for the treatment of plaque psoriasis: results from the randomized phase 3 CIMPACT trial

BACKGROUND: Certolizumab pegol (CZP) is an Fc‐free, PEGylated anti‐tumor necrosis factor biologic. OBJECTIVES: To report 3‐year outcomes from the CIMPACT (NCT02346240) phase 3, CZP in moderate to severe plaque psoriasis, randomized controlled trial. METHODS: Adults were randomized 3:3:3:1 to CZP 200...

Descripción completa

Detalles Bibliográficos
Autores principales: Warren, R. B., Lebwohl, M., Sofen, H., Piguet, V., Augustin, M., Brock, F., C. Arendt, Fierens, F., Blauvelt, A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Psoriasis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9290019/
https://www.ncbi.nlm.nih.gov/pubmed/34192387
http://dx.doi.org/10.1111/jdv.17486

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9290019/
https://www.ncbi.nlm.nih.gov/pubmed/34192387
http://dx.doi.org/10.1111/jdv.17486

Ejemplares similares